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Abstract
Due to their self-renewal and tumorigenic properties, tumor-initiating cells (TICs) have been
hypothesized to be important targets for colorectal cancer (CRC). However the study of
TICs is hampered by the fact that the identification and culturing of TICs is still a subject of
extensive debate. Floating three-dimensional spheroid cultures (SC) that grow in serum-
free medium supplemented with growth factors are supposed to be enriched in TICs. We
generated SC from fresh clinical tumor specimens and compared them to SC isolated from
CRC cell-lines as well as to adherent differentiated counterparts. Patient-derived SC display
self-renewal capacity and can induce serial transplantable tumors in immuno-deficient
mice, which phenotypically resemble the tumor of origin. In addition, the original tumor tis-
sue and established SC retain several similar CRC-relevant mutations. Primary SC express
key stemness proteins such as SOX2, OCT4, NANOG and LGR5 and importantly show
increased chemoresistance ability compared to their adherent differentiated counterparts
and to cell line-derived SC. Strikingly, cells derived from spheroid or adherent differentiating
culture conditions displayed similar self-renewal capacity and equally formed tumors in
immune-deficient mice, suggesting that self-renewal and tumor-initiation capacity of TICs is
not restricted to phenotypically immature spheroid cells, which we describe to be highly
plastic and able to reacquire stem-cell traits even after long differentiation processes.
Finally, we identified two genes among a sphere gene expression signature that predict dis-
ease relapse in CRC patients. Here we propose that SC derived from fresh patient tumor
tissue present interesting phenotypic features that may have clinical relevance for chemore-
sistance and disease relapse and therefore represent a valuable tool to test for new CRC-
therapies that overcome drug resistance.
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Introduction
Colorectal carcinoma (CRC) is the third most frequently diagnosed cancer type for both men
and women and the second most common cause of cancer mortality in Western countries [1].
Despite great progress made during the last decades, a lot of controversy still remains over the
backgrounds of cancer onset, metastasis and CRC progression. The two dominant concepts of
carcinogenesis postulate stochastic (clonal evolution model) and hierarchic (cancer stem cell
model) organization of tumors. According to the latter, subsets of cells, the so-called tumor-ini-
tiating cells (TICs) also known as cancer stem cells (CSCs) are responsible for tumor evolution
[2].
TICs have first been described in the frame of hematopoietic malignancies [3]. A few years
later, TICs were also identified in a wide array of solid tumors such as, breast [4,5], skin [6],
brain [7–9], pancreas [10], lung [11] and colon [12,13]. TICs are defined by their (1) self-
renewal, (2) differentiating and (3) tumor-initiating capacity. They have been described to
propagate tumors that are capable of recapitulating the heterogeneity of primary tumors [3].
The high tumorigenic potential of TICs is aggravated by their strong resistance to radio- and
chemo-therapy. TICs are able to evade DNA damage during radiation and chemotherapy by
reduction of ROS and enhanced activity of DNA checkpoint kinases [14]. The remaining sub-
set of TICs might induce the formation of new tumors, thereby leading to a rapid relapse of the
malignancy [15]. As a result, TIC-specific treatments could potentially lead to a reduced risk of
tumor recurrence and an improved prognosis for CRC patients. Interestingly, various recent
studies support the clinical relevance of targeting TIC-associated genes [16].
Despite significant advances in colon TIC research, the isolation, identification and charac-
terization of colon TICs remains incompletely established. Different strategies can be adopted
to gain colon TICs out of tumor tissue. Isolation techniques for TICs are based either on their
immunogenic or functional properties [17]. The antigenic approach takes advantage of a vari-
ety of cell surface markers, for example prominin-1 (commonly known as CD133), CD44,
CD34, CD24, epithelial-specific antigen (EpCAM/ESA), CD166, CD29, Lgr5, CD49f and
ALDH-1 [17]. Functional isolation of TICs relies on diverse characteristics, such as anchorage-
independent growth, chemoresistance, self-renewal, asymmetric division, and pluripotency.
Over the last years spheroid cultures (SC) that rely on the anchorage-independent growth
properties of stem cells, have been used to enrich for TICs in brain [18,19], breast [5,20], and
colon [12,21,22] tissue. It is well accepted that SC preserve more faithfully the characteristics of
original tumors, including gene expression profiles, tumor heterogeneity and tumor morphol-
ogy, compared to regular adherent cultures [12,19,21–25]. Additionally, spheroids mirror the
3D cellular context and relevant pathophysiological gradients of in vivo tumors [26]. However,
to which extent sphere formation assays favor the enrichment of TICs is not fully clear yet.
First, it is noteworthy that spheroids also contain differentiated tumor cells [21,22,27,28]. Sec-
ond, some studies on CRC could indeed demonstrate that SC possess TIC characteristics
[12,21,29–31], whereas others could not find any enrichment when comparing them to adher-
ent differentiated cultures [31–36]. Importantly most of the aforementioned studies are based
on cell lines. It can be speculated that the inconsistent observations gained with cell lines might
be due to phenotypic differences between selected clones that might have occurred over long
periods of cell culture [37].
Considering these conflicting results, we decided to characterize SC from different origins
in the light of TIC enrichment. In contrast to traditional cell lines, patient-derived primary cul-
tures reflect the heterogeneous nature of tumor biology, as it exists in patients. Thus, the
importance of this study is to characterize generated SC directly derived from fresh surgical
specimens and compare them to their adherent differentiated counterpart as well as to SC
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derived from CRC cell lines. We want to determine if SC exhibit features of stemness, including
self-renewal, stem cell marker expression, differentiation potential, resistance to chemotherapy
and tumorigenicity in vivo.
Material and Methods
Generation of primary SC and their differentiated counterparts
Human colon tissue samples were collected by the Integrated Biobank of Luxembourg (IBBL,
www.ibbl.lu) in accordance with institutional guidelines. All human samples used in the scope
of this work were donated freely and written informed consent was obtained from the donor
for the use of this sample in research. Ethical approval was obtained from the Comité National
d'Ethique de Recherche, Luxembourg (Reference 201009/09). Freshly resected colon tumor tis-
sue from 35 CRC patients was collected and immediately processed in culture. Tissue was
washed several times in serum-free Dulbecco’s modified Eagle medium (DMEM)-F12 supple-
mented with antibiotic-antimycotic agent (Invitrogen). The specimens were minced into 1–2
mm3 pieces followed by incubation in collagenase type IV (0.05 mg/ml; Invitrogen) and hyal-
uronidase (2 μg/mL; Sigma) for 1 hour at 37°C. Single cell suspension was obtained by mixing
every 15 minutes and by filtration through a 70 μm cell strainer (BD Biosciences). Primary
colon SC were maintained in ultra-low attachment (ULA) cell culture vessels (Corning) in
serum-free stem cell medium containing DMEM-F12 supplemented with B-27 (1x) and N-2
(1x) supplements (Invitrogen), BSA (4 mg/mL; Roth), non-essential amino acids (1x; Sigma),
glucose 0.15% (Sigma), Insulin (4 U/L; Sigma), Heparin (4 μg/mL), N-Acetylcystein (1 mM;
Sigma), EGF (20 ng/mL; Biomol), bFGF (20 ng/mL; Miltenyi Biotec), and penicillin/streptomy-
cin (1x; Lonza). This medium will further be referred to as stem cell medium (SCM). For char-
acterization purposes, we only used early passage SC within this study (not more than 15
passages).
We generated adherent-growing differentiated cultures from SC at very early passages. For
this, differentiating conditions were applied: early spheroids were dissociated and cultured in
DMEM-F12 supplemented with 10% FCS and 1% penicillin/streptomycin in regular cell cul-
ture vessels. In contrast to SC, differentiated cultures grow as adherent cells. These cultures
were maintained under differentiating conditions for at least 5 passages before being used for
experiments.
Spheroid cultures derived from CRC cell lines
HT29, HCT116, LS174t, SW480, and SW620 CRC cell lines were obtained either from the Amer-
ican Type Culture Collection (ATCC, Rockville, USA) or the German Collection of Microorgan-
isms and Cell Cultures (DSMZ, Braunschweig, Germany) and maintained in recommended
culture conditions. For the culture of SC, cell lines were grown in serum-free DMEM-F12 supple-
mented with B-27 (1x; Invitrogen), Insulin (4 U/L; Sigma), Heparin (4 μg/ml; Sigma), EGF (20
ng/mL; Biomol), bFGF (20 ng/mL; Miltenyi Biotec), and penicillin/streptomycin (1x; Lonza).
Cell line identity was confirmed by short-tandem repeat genotyping at DSMZ.
3D spheroid invasion assay
5000 cells of SC were plated in round-bottom 96-well ULA plates in 100 μl DMEM-F12
medium with 1% penicillin/streptomycin. After 3 days of sphere formation, 10% FCS and
1.25 mg/ml collagen (PureCol, CellSystems) were added. After 1h of solidification, the spher-
oid/collagen suspension was overlaid with 100μL/well DMEM-F12 with 10% FCS. Invasion
was monitored by measuring the maximal spheroid outgrowth diameter after 7 days.
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Cell growth and proliferation
Adherent cells were seeded in 6-well plates and SC in ULA 6-well plates in their respective
medium. After 5 days, cells were dissociated into single-cell suspension, stained with Trypan
blue and counted with a cell counting device (CEDEX, Roche).
In vitro limiting dilution sphere formation assays
SC were dissociated in TrypLE Express (Gibco) by pipetting up and down for 1 minute, incu-
bated at 37°C for 3 minutes and passed through a 40 μm cell strainer (BD Biosciences) to
obtain single cell suspensions. Single cell assay: Cells were seeded at a density of 1 cell per well
in a 96-well plate at a final volume of 100 μl. Single cell seeding efficiency was approximately
30% and only wells that initially contained single cells were evaluated for subsequent analyses.
Spheroids were counted after 10–14 days, depending on the growth rate of the different pri-
mary SC. 50–60 single cells per condition were analyzed for sphere formation and only spheres
bigger than 50 μm in size were included in the analyses. The extreme limiting dilution analysis
ELDA software (http://bioinf.wehi.edu.au/software/elda/) [38] was used to determine the esti-
mated stem-cell frequency for single cell assays. 1000 cell assay: 1000 cells/well were seeded in
an ULA 6-well plate and spheroids were counted after 7 days.
Immunofluorescence
Immunofluorescence was performed on cytospins (EZ Cytofunnels) (Thermo Scientific) for
SC and on coverslips for adherent cell cultures. Samples were fixed with ice-cold methanol for
10 minutes at -20°C, blocked with a 3% BSA/PBS solution followed by incubation overnight at
4°C with the primary antibody. Secondary antibody was applied for 1 hour at room tempera-
ture; samples were mounted with DAPI-containing Fluoromount G (Southern Biotech) and
analyzed on a confocal microscope (Zeiss LSM 510 Meta). To certify that the staining was posi-
tive throughout the whole spheroid, z-stacks were performed. The antibodies used are listed in
S1A Table.
Fluorescence activated cell sorting and flow cytometry
For flow cytometry, samples were prepared as previously described (Shmelkov et al, 2008) and
run on a FACS Canto II. The primary antibodies used are listed in S1B Table.
Real-time qPCR
AllPrep extraction kit (Qiagen, Hilden, Germany) was used to extract RNA. cDNA was
obtained by reverse transcription using the high capacity cDNA reverse transcription kit
(Applied Biosystems). ABsolute Blue qPCR SYBR Green Low ROXMix (Thermo Scientific),
2.5 pmol of each primer and 5 ng of cDNA per reaction was used and the reaction was run on a
7500 FAST Real time PCR Detection System (Applied Biosystems) cycler with the following
settings: 40x (95°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec). Expression levels of the
gene of interest were normalized against multiple reference genes [39] using the qbase+ soft-
ware [40], according to the MIQE guidelines. The used reference genes were: EFF1A1, B-Actin,
28S, YWHAZ. Primer pairs used for RT-qPCR are shown in S1C Table.
Colony formation assay
Cells derived from SC or differentiated cultures were seeded at different densities of 250, 100,
50, 20 cells/well in differentiating medium containing serum. After 10 days, colonies were
stained and counted under a microscope.
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Chemosensitivity assays
In order to assess chemoresistance we applied different assays. The first assay was based on a
3D spheroid system, where cells derived from SC or differentiated counterparts were seeded in
a round-bottom 96-well ULA plate at a density of 5000 cells/well in serum-free DMEM-F12
supplemented with 1% penicillin/streptomycin. After 3 days of spheroid formation, 5-Fluoro-
uracil (5-FU) (Sigma) was added at varying concentrations. Sphere size was measured every
24 hours for 5 days and sphere shrinkage was assessed by determining the relative sphere size
of control and treated conditions. The second assay was based on a 2D monolayer system
using the cell proliferation reagent WST-1 (Roche, Germany). For this, 30.000 cells of both SC
and the differentiated counterparts were plated in 96-well plates in 200 μL of DMEM-F12
medium, supplemented with 10% FCS and 1% penicillin/streptomycin medium with or with-
out 50 μM 5-FU. WST-1 was added at a 1:10 final concentration after 5 days and incubated for
1 h at 37°C and the relative survival was determined. In addition we performed single cell and
colony forming assays in presence of 5μM 5-FU for the assessment of chemoresistance.
In vivo tumor formation assays
Non-obese diabetic/severe-combined immunodeficient (NOD/SCID) mice were obtained
from Harlan Laboratories Netherlands and experiments performed according to all applicable
laws and regulations subsequent to approval by the institution’s animal care and ethical com-
mittee of the University of Luxembourg (Permit Number: 14-MDM-02). Tumor-initiating
capacity of SC in NOD/SCID mice was assessed by preparing serial dilutions of cells (10. 000,
1000, 100 and 10 cells; 5–6 injections/cell dose). Single cells were resuspended in 100 μL of 1:1
mixed serum-free medium and matrigel (BD Biosciences) and injected subcutaneously in the
flank of 6-week-old mice. Tumor growth was followed 1–2 times a week and tumor volume
was calculated by the formula LW2/2. Any mice showing severe signs of weight loss or distress
or a tumor size reaching 1000 mm3 were removed from the study and euthanized to avoid
unnecessary pain and discomfort according to the ethical guidelines. For serial transplanta-
tions, tumors were explanted, dissociated in culture and re-injected in second recipient mice.
Sections of generated xenografts were stained with eosin and hematoxylin and analyzed by a
pathologist. To directly compare SC with their differentiated counterpart, we chose the lowest
dose tested (10 cells/injection for T20 and 100 cells/injection for HT29; n = 5) and cells derived
from differentiated or spheroid cultures were injected on right and left flank respectively.
Microarrays and mutation profiling
The microarrays were performed at the Luxembourg Institute of Health (LIH) after RNA qual-
ity and purity check using a 2100 Bioanalyzer (Agilent Technologies). Affymetrix gene chip
Human Gene ST v2.0 arrays were prepared in accordance with the standard protocol. Microar-
ray data were preprocessed using the Robust Multiarray Analysis (RMA) algorithm with GC-
correction using commercial software Partek Genomic Suite (version 6.6, Copyright 2015, Par-
tek Inc., St. Louis, MO, USA). Three replicates were run for all conditions for microarrays
except T18 for which we ran 4 technical replicates. We had to withdraw one sample of the
HCT116 cell line, because of its low quality after hybridization. Data were analyzed and the
results visualized in R/Bioconductor (version 3.1.2). Microarray data are available in the
ArrayExpress database under accession number E-MTAB-3575. Top mutations were assessed
using the TruSeq Amplicon-Cancer panel (TSACP) with the MiSeq platform according to the
Illumina guidelines with the following criteria: depth of> 1000 and a variant frequency
of> 0.05. For ethical purposes we were not able to include the mutational profile for
patient T6.
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Differential gene expression and survival analysis
Microarrays (ArrayExpress database, accession number E-MTAB-3575) were performed in
accordance with standard protocols (see supplementary material and methods section). Differ-
entially expressed genes between SC and the respective differentiated counterparts were deter-
mined using linear modelling with empirical Bayesian approach realized in limma package
(http://www.bioconductor.org/packages/ release/bioc/html/limma.html). A common sphere
gene signature between primary and cell line derived SC was determined as intersection of up-
regulated genes with FDR<0.05 and log-fold change log2FC>0.6. Two independent publicly
available datasets from a collection available in the database PROGgeneV2 [41] containing
data on the overall survival of CRC patients were used to generate survival curves: GSE17536
[42] composed of 177 patient samples and GSE29621 [43] consisting of 64 patient samples. We
found a significant association with poor patient survival in these 2 datasets among a collection
available in the aforementioned tool. The dataset GSE39582 [44] consisting of 566 patient sam-
ples was used to investigate the effect of the identified sphere gene signature on the disease-free
survival.
Statistical analysis
GraphPad Prism 5 software was used for statistical analysis. We used unpaired Student t test to
compare 2 conditions and 2-way ANOVA test with Bonferroni post-tests to compare treat-
ment effects over time. All experiments were performed in at least 3 independent experiments
unless otherwise stated.
Results
Generated SC derived from primary tumor tissue retain characteristics of
original tumors
We first assessed the ability to enrich for TICs in CRC specimens using several of the previ-
ously reported potential surface markers. The expression of putative stem cell markers CD44,
CD24, EpCAM, CD166 and CD133 was analyzed by flow cytometry. We found that patient
biopsies are highly heterogeneous in terms of phenotypic markers (S1 Fig), questioning their
reliability for the identification of TICs. We further decided to sort cells directly from patient-
or cell line-derived SC according to their CD133 expression and performed functional single
cell assays. The sphere forming cell (SFC) frequency was similar among the CD133 low,
medium and high population (S1 Fig), suggesting that CD133 expression does not correlate to
enhanced sphere-forming capacity. Along the same line, several in vivo studies show that
CD133+ and CD133- cells form tumors with similar efficiency [34,45,46]. Overall, these results
suggest that putative TIC markers are not reliable for the identification of TICs in our system.
SC may reflect tumor heterogeneity as it exists in patients and have been described to be
enriched in TICs. We collected fresh colon cancer tissue from 35 patients who had not received
chemotherapy or radiotherapy prior to surgery. After enzymatic digestion, single cell suspen-
sion was plated in SCM in order to promote spheroid growth. Tumor specimens of 5 out of 35
patients (15% efficiency) led to stable primary SC that we were able to maintain in culture for
extended passages (more than 20 passages) (Fig 1A and S2 Table). The remaining colon cancer
tissues did not lead to sphere formation or lost their sphere-forming capacity after a few pas-
sages. It is noteworthy that the success rate observed is comparable to other attempts to estab-
lish SC from colorectal tumor tissue [47,48]. The biopsies that gave rise to stable SC were of
various histological stages of CRC (S2 Table). Three primary SC T6, T18 and T20, which
represent stage IIIC, stage IIA and stage IVA CRC respectively, were chosen for
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characterization (S2 Table). Interestingly, SC derived from T6 and T20 patients showed an
increased invasive capacity compared to the T18 spheroid culture, which was derived from an
earlier stage, namely stage II (Fig 1B and 1C). This result suggests that SC derived from primary
tumors may retain the invasive properties of their tumor of origin. However, this observation
needs to be further addressed in much larger cohort studies. Notably, several CRC-relevant
mutations detectable in the tumor of origin were also present in the primary SC (S2 Fig). We
additionally established adherent differentiated counterparts of the primary SC (Fig 1A and
Material and Methods section). The comparison of SC with their respective differentiated
counterparts from the same patient might allow studying SC-specific properties in regard to
TICs. In presence of serum, SC change their phenotype and grow as an adherent cell layer.
Interestingly, adherent differentiated counterparts showed increased proliferation compared to
SC (S3 Fig). Besides using primary tumor tissue, we also tested the ability of CRC cell lines to
form SC. HT29, HCT116, LS174t, SW480 and SW620 cell lines gave rise to spheres over several
passages while maintained in SCM (Fig 1A and data not shown). Consistent to SC derived
from primary tissue, HT29- and HCT116- derived SC displayed a lower proliferation rate com-
pared to their parental adherent counterpart (S3 Fig). This observation, which is in line with
previous studies [35,36], reveals that upon differentiation, TICs acquire increased proliferative
properties. In the following experiments, we focused on the extensive characterization of 3 SC
established from primary patient material and 2 SC derived from CRC cell lines, namely HT29
and HCT116.
Fig 1. Description of generated SC. (a) Morphological features of 2 CRC cell lines (HT29, HCT116) and 3 primary patient tumors (T6, T18, T20) grown as
SC (S, left panel) and their differentiated counterparts (D, right panel). (b) 3D spheroid invasion assay of SC derived from primary tumor tissue T6, T18 and
T20. Representative pictures of embedded spheroids after 7 days of invasion. (c) Quantification of the maximal spheroid outgrowth diameter (μm) after 7
days of invasion. Representative figure of 3 independent experiments, scale bar = 100 μm. Data are presented as mean ± SD (n = 8); *P<0.05, **P<0.01.
doi:10.1371/journal.pone.0146052.g001
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Spheroid cultures show expression of stemness proteins
In order to investigate in more detail the phenotypic differences between SC and the respective
differentiated counterparts, we analyzed the expression of key stemness proteins such as SOX2,
OCT4, NANOG and LGR5 as well as CK20, a key epithelial differentiation marker. The tran-
scription factors OCT4, SOX2 and NANOG are known as master regulators of pluripotency
and are responsible for maintaining an undifferentiated state [49] as well as favoring self-
renewal capacity of TICs [50]. SC displayed high levels of stemness proteins whereas CK20 was
barely expressed (Fig 2A). Importantly, the adherent differentiated counterparts expressed
CK20 and lost the expression of key stemness proteins. Similarly to protein levels, the expres-
sion of key stemness genes was increased in SC compared to differentiated cultures (Fig 2B).
Interestingly, LGR5 is highly expressed in primary SC, in contrast to SC derived from CRC cell
lines (Fig 2A and 2B). We also assessed the expression of β-catenin, a functional marker of
CRC stemness, and found a higher expression in SC (Fig 2B). Altogether, these data show that
SC display higher levels of stemness and lower levels of epithelial differentiation markers.
Spheroid cultures and adherent differentiated counterparts display
similar self-renewal and tumor-initiation capacity
We were interested in determining functional differences in regard to TIC properties between
SC and adherent differentiated counterparts. At first, we tried to perform sphere formation
assays by plating different cell densities. Many studies on TICs show self-renewal capacity
using sphere formation assays by seeding high numbers of cells per well. However, in our expe-
rience and as already mentioned by others [33], plating high cell densities leads to sphere for-
mation through aggregation and fusion followed by subsequent proliferation rather than
through self-renewal capacity of a cell, thereby falsifying the sphere forming capacity results
(S4A Fig). Thus, to ensure true clonality and not fusion or aggregation of cells we performed
sphere formation assays at the single cell level. The 3 stable primary SC and the 2 SC derived
from CRC cell lines all displayed self-renewing capacity that was maintained over several pas-
sages (Fig 3A). For patient T6, there was 1 sphere forming cell (SFC) in 9.14 cells for passage 1,
1 SFC in 7.51 cells for passage 2, and 1 SFC in 11.66 cells for passage 3 (S3 Table). Strikingly,
T20, derived from a patient who had already metastasis at the time of resection, showed an
increased SFC frequency compared to T6 and T18 (S3 Table). Interestingly, the SFC frequency
rises from early passages (passage 5) to late passages (passage 15–25), thus suggesting that cul-
tures maintained in stem-cell enriching conditions show increased TIC behavior over time (Fig
3B). Even after long-term culture in SCM, SC that are transferred to differentiating culture con-
ditions have still the capacity to adhere and morphologically resemble the differentiated coun-
terpart or the parental cell line (Fig 1A and S5D Fig).
Next, we studied the tumorigenic potential of SC. Primary SC generated from tumor tissue
of patients T6, T18 and T20 were able to induce tumor formation in NOD/SCID mice with cell
numbers ranging from 10.000 cells to 10 cells per injection (Fig 4A). TIC frequency varied
from 1 in 6 to 1 in 22 spheroid cells depending on the respective patient sample (S4 Table).
Similarly, SC derived from CRC cell lines also initiated tumor growth in mice with cell num-
bers ranging from 10.000 cells to 100 cells (S6A Fig and S4 Table), though HCT-116 SC had a
lower tumor incidence compared to primary SC (S4 Table). In both cases, tumor weight nicely
correlated with injected cell numbers (Fig 4B and S6B Fig). Interestingly, primary SC estab-
lished from tumor specimen of patient T20 were able to induce tumor formation in mice much
faster with higher tumor incidence compared to T6 and T18 SC (Fig 4A and S4 Table). The
phenotype of T20-derived SC, which is characterized by high SFC frequency, tumor incidence
and tumor proliferation underlines and recapitulates the aggressive nature of the primary
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Fig 2. Increased expression of stemness regulators in SC. (a) Immunofluorescence staining of SC
reveals an increased expression of key stemness proteins SOX2, OCT4 and LGR5, and a decreased
expression of the CRC differentiation marker CK20 compared to adherent differentiated counterparts.
NTERA-2 human embryonal carcinoma cells were used as positive control for staining and showed similar
signal intensity for all assessed pluripotency markers (data not shown). Magnification 40x. (b) Gene
expression of key stemness genes of SC and differentiated counterparts. Representative figure of 3
independent experiments. Data are presented as mean ± SD, *P<0.05, **P<0.01, ***P<0.001, ns = not
significant.
doi:10.1371/journal.pone.0146052.g002
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tumor of patient T20. Six to fifteen weeks after primary transplantation, tumors were
explanted, dissociated into single cells and serially transplanted into secondary recipient mice.
Injections of 10.000 and 1000 cells allowed the formation of a tumor in secondary recipient
mice. Histology assessment of the resulting primary and secondary xenografts by a pathologist
confirmed the resemblance to the original primary tumor except that T20 lost some differentia-
tion potential through serial transplantation (Fig 4C). Thus, SC isolated from primary human
tumor samples do not only possess tumor-initiating capacity, but they also recapitulate the
phenotype of the primary tumor (Fig 4C).
We then thought to directly compare self-renewal capacity of adherent differentiated and
spheroid cultures. For this, we assessed the ability for self-renewal in the form of colonies for
adherent differentiated cultures and of spheres for SC by plating single cells and counting colo-
nies and spheres, respectively. We could not observe a drastic difference in self-renewal
between the two culture types (Fig 5E and S5E and S5F Table), although for T6 differentiated
cultures were able to form colonies in 55% of the cases (Fig 5D and S5E Table) whereas SC gen-
erated spheres with 75% efficiency (Fig 5E). Adherent differentiated cultures did not form any
spheres when maintained in differentiating culture conditions (S4B Fig). However, when these
Fig 3. Self-renewal capacity is maintained over several passages. (a) Sphere formation rates were determined over several generations (gen.) by
seeding single cells of early passage SC grown from primary tumor tissue and CRC cell lines. Data are presented as mean ± SD. (b) Self-renewal capacity of
early (passage 5) and late (passage 15–25 depending on the tumor) SC from primary tumor tissue. Data are presented as mean with 95% confidence
interval.
doi:10.1371/journal.pone.0146052.g003
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cells were reversed to SCM conditions they were able to form spheres to similar extent, as did
cells derived from SC (Fig 5E and S4B Fig). We might reason that cells from adherent differen-
tiated cultures may rapidly reacquire a TIC phenotype, suggesting a high plasticity of these
cells. Furthermore, the size of spheres originating from single cells, a measurement of cell pro-
liferation, was determined for both cultures. Strikingly and in accordance with our
Fig 4. SC are highly tumorigenic but do not show differences in tumor incidence compared to
adherent differentiated counterparts. (a) Primary SC induce tumors in mice. (b) Tumor weight of the
generated tumor xenografts from primary SC. (c) Xenograft derived from primary SC recapitulate the
phenotype of the primary tumor after serial transplantation in mice. Magnification 10x. (d) Tumor growth in
mice after injection of SC and their differentiated counterpart. Tumor incidence is indicated within the graph.
Data are presented as mean ± SEM, *P<0.05.
doi:10.1371/journal.pone.0146052.g004
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Fig 5. SC are more resistant to 5-FU treatment. (a) Experimental layout of the sphere formation and chemosensitivity assay. (b) Relative sphere size of SC
and their differentiated counterparts exposed to different concentrations of 5-FU over 5 days. Representative figure of 2 independent experiments. Statistics
are shown in S5A–S5D Table. (c) Relative survival of SC and their differentiated counterparts after exposure to 50 μM 5-FU for 5 days. Representative figure
of 2 independent experiments is shown. Data are presented as mean ± SD (n = 8), *P<0.05, **P<0.01, ***P<0.001, ns = not significant. (d-e) Clonogenic
and self-renewal capacity of SC and adherent differentiated counterparts were assessed by performing colony- or sphere-formation assays respectively.
5FU (5μM) was used to assess chemoresistance in both culture types. For T6, 2 independent experiments were performed whereas one single experiment
was performed for HT29.
doi:10.1371/journal.pone.0146052.g005
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proliferation assays, spheres derived from differentiated cultures were bigger in size compared
to spheres from SC (S3 Fig). In addition we performed colony-forming assays using different
cell densities with both culture conditions. The number of colonies did not differ significantly
between SC and adherent differentiated counterparts (Fig 5D and S5E and S5F Table). Again
colonies were bigger in size when derived from differentiated cultures (S3 Fig). Altogether,
these data suggest that cultures maintained in SCM or adherent differentiation conditions dis-
play similar self-renewal capacity. In addition SC display a weaker proliferation than their
adherent counterpart. We further investigated whether passage through xenografts may influ-
ence the phenotype of TICs. Xenograft-derived spheres showed similar self-renewal capacity to
SC derived from primary tissue or CRC cell lines (S5A and S5B Fig) and for some cases even
showed a reduced number of spheres or an altered phenotype (S5C Fig). In order to compare
the in vivo tumorigenic potential of primary SC and their differentiated adherent counterpart,
we injected single cell suspensions of both conditions in NOD/SCID mice. SC showed a ten-
dency for faster tumor growth rate than the differentiated counterpart, which was significant in
the early time points (Fig 4D). However, tumor incidence was similar between both groups
(Fig 4D), suggesting that tumor-initiating capacity of TICs is not restricted to phenotypically
immature spheroid cells. Of note, resected xenografts derived from SC and differentiated coun-
terparts displayed similar expression patterns of stemness genes (S6C and S6D Fig).
Spheroid cultures are more resistant to chemotherapeutic treatments
than adherent differentiated cultures
In order to be able to compare SC and their differentiated counterparts, the same culturing
conditions and the same culture medium were applied for both groups and different assays
were performed (see Material and Methods section). In the first assay, we decided to use 3D
cell culture models to explore the resistance to chemotherapeutics as they have been shown to
provide more relevant and translational observations [51]. Cells were plated in round-bottom
ULA plates in order to allow the formation of a sphere followed by treatment with 5-FU at dif-
ferent concentrations and sphere size was recorded (Fig 5A and 5B). The second assay mea-
sures the metabolic activity of the cells after 5-FU treatment and thereby reflects their survival
rates (Fig 5C). Primary SC showed higher resistance to 5-FU treatment and a higher relative
survival rate compared to their differentiated counterparts (Fig 5B and 5C). HCT116 SC and
the differentiated counterpart failed to form a unique sphere for the setup of the first assay;
therefore, we only included the relative survival assessment for this cell line (Fig 5C). Interest-
ingly, in contrast to primary SC, cell line-derived SC display less resistance to 5-FU treatment
(S5A–S5D Table), which can also be observed while analyzing the survival rates; in HCT116,
no difference was observed in survival rates after 5-FU treatment between SC and differentiated
counterpart (Fig 5C) and in HT29 the difference between both conditions was less prominent
and significant compared to primary SC (Fig 5C and S5D Table). As the first assays described
are based on sphere size and metabolic activity, which rather reflects cell proliferation, we addi-
tionally performed colony and sphere forming assays to assess self-renewal and clonogenic
capacity of SC and adherent differentiated cultures. Strikingly, while performing colony form-
ing assays for both culture types, we could observe a drastic reduction in colony formation
after 5-FU treatment in adherent differentiated cultures compared to SC (Fig 5D). Consistently,
sphere-initiating frequency was barely altered after 5-FU treatment in SC whereas a decrease in
sphere numbers could be observed for adherent differentiated cultures (Fig 5E). Of note, after
5-FU treatment sphere formation was slightly reduced in cells derived from traditional cell
lines (HT29 SC), whereas no difference could be observed for cells derived from primary
tumor tissue (T6 SC) (Fig 5E). This observation is in line with the results obtained in the two
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other chemoresistance assays, which might suggest that cell-line derived SC are more sensitive
to conventional therapy than SC derived from primary tumor tissue. Different mutational pro-
files could be the basis for the observed differences in drug response. However, the mutational
status of several relevant CRC mutations was identical between SC and their differentiated
counterparts and no major differences could be observed between SC derived either from
HT29 cell line or from primary tumor tissue (S2 Fig). Taken together, all the described experi-
ments show that SC display increased resistance to chemotherapeutics compared to adherent
differentiated cultures. The increased sensitivity to 5-FU is consistent with the high prolifera-
tion rate of the adherent cultures, as chemotherapeutics are known to mostly target fast-prolif-
erating cells. SC from primary tumor tissue might therefore represent an interesting tool for in
vitro studies of new CRC therapies as these culture conditions favor the enrichment of cells
that are highly resistant to conventional therapies and that need to be targeted to circumvent
disease relapse.
Gene signature derived from spheroid cultures predicts for poor patient
outcome in CRC
We could identify a common sphere gene signature consisting of 8 genes that were commonly
up-regulated among the primary and cell line-derived SC in comparison to their respective dif-
ferentiated counterparts (Fig 6A and S6 Table). The 8-gene expression signature was able to
predict poor overall survival in CRC patients (Fig 6B). The clinical relevance of the sphere sig-
nature could be confirmed in a second cohort of CRC patients among a collection of datasets
available in the PROGgeneV2 tool [41] (S7A Fig). However, as most patients suffering from
CRC are already at an advanced age and thus may die from another reason than from CRC,
overall survival assessment might not be the adapted measure for patients’ outcome. Two
genes, namely CDA and GST4A out of the 8 gene signature are known to be associated with
chemoresistance [52–54]. Interestingly, the expression of these genes, either combined or sepa-
rate, was found to be linked with an increased risk of disease relapse in a large patient cohort
covering 565 patients (dataset GSE39582) (Fig 6C and S7B and S7C Fig).
Discussion
We first thought to select TICs by using well-described markers. However, while assessing the
expression of CD133, CD44 and CD24 in primary tumor CRC tissue and in SC derived from
patient material, we observed a very heterogeneous expression. In agreement with our data,
several recent studies also showed high variability in the expression of surface markers between
different patients, ranging from no or little expression to 90% positivity for the same marker
[23,34,48,55]. It has further been demonstrated that culturing conditions (including cell den-
sity and passage number) influence surface marker expression to a high degree [56]. Impor-
tantly, neither SC derived from patient material nor established cell lines did show any
difference in sphere-forming frequency when flow-sorted according to their CD133 expression.
Accordingly, over the last years, many reports challenge the view of CD133 as a universal TIC
marker [57]. Thus, it seems delicate to rely on surface markers for the isolation of colon TICs.
Another way of identifying TICs is based on their functional characteristics. We established
SC in which cells grow in an anchorage-independent manner. In agreement with others
[12,19,22,24,30], we provide evidence that SC retain the characteristics of the tumors of origin.
A recent study by Lee and colleagues suggests that patient-derived SC have similar mutational
and genotype profiles to original CRC tumors [23]. Accordingly, most CRC relevant mutations
were maintained between the tumor of origin and our generated SC. We extended our study by
characterizing these SC in regard to TIC properties. Generated patient-derived SC harbor
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Fig 6. Gene signature derived from SC predicts poor outcome in CRC patients. (a-b) An overlap of 8
commonly up-regulated genes for patient and cell line-derived SC (listed in S6 Table) predicts for overall
survival in CRC. (b) The combined expression of two genes,CDA &GSTA4, is linked to an increased risk of
disease relapse. The number of patients in each group is mentioned within the brackets; significant p-value is
indicated.
doi:10.1371/journal.pone.0146052.g006
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increased expression of stemness proteins, a property of stem cells and their tumorigenic coun-
terparts [50] and show high self-renewal capacity. Mice transplanted with 100 cells of T6, T18
and T20 all initiated tumor growth, which shows the tumorigenic potential of SC derived from
primary tumor tissue. Barrett and colleagues showed that the self-renewal capacity of glioma
TICs, determined by the ability of cells to form sphere cultures, is not associated with the
tumor growth potential in mouse models; cells with a low self-renewing capacity led to more
aggressive tumors in vivo compared to higher self-renewing cells [58]. In contrast, we and oth-
ers [12,59] show that sphere formation correlates to in vivo tumorigenicity; the phenotype of
T20-derived SC, which is characterized by high SFC frequency, also shows a higher tumor inci-
dence and faster tumor growth, thereby recapitulating the aggressive nature of the primary
tumor of patient T20. Nevertheless, this observation needs to be addressed with additional pri-
mary SC. In line with Dieter and colleagues we show that long-term passaging of cells under
spheroid culture conditions allows for the enrichment in TICs [48]. Importantly, the estab-
lished primary SC were all capable of tumor initiation at really low cell doses, the gold standard
method to evaluate for the presence of TICs.
Interestingly, at the beginning of tumor outgrowth, T20 and HT29 SC show faster tumor
growth in vivo compared to their differentiated counterpart. However, sphere formation in
vitro and tumor incidence in immune-deficient mice were similar between cells maintained
under spheroid or differentiating culture conditions, suggesting that self-renewal and tumor-
initiation capacity is not restricted to phenotypically immature spheroid cells but might instead
be attributed to highly proliferative progenitors. These results are in line with other studies
comparing differentiated and SC derived from cell lines that showed similar tumorigenic
potential for both culturing methods [29,32,35,60]. Our observations agree with the dynamic
TIC model that has recently been proposed by Vermeulen and colleagues [15,27]. Indeed, a
xenograft might provide a microenvironment that affects plasticity and dedifferentiation pro-
cesses of tumor cells [61]. Stromal cell-secreted factors have been shown to restore the TIC
phenotype by upregulating the Wnt cascade in more differentiated tumor cells both in vitro
and in vivo [27]. Along this line, similar expression of stemness genes was observed in xeno-
grafts derived from SC and their differentiated counterpart. Furthermore, we could observe a
reversible phenotype when differentiated cultures were exposed to serum-free conditions in
presence of growth factors. Altogether, these results suggest a pronounced plasticity of TICs,
which needs to be considered for the development of TIC-specific therapies. Further studies
will focus on the influence of the microenvironment on the identified plasticity of TICs.
In contrast to hematopoietic malignancies, conventional therapy regimes in solid tumors
have only marginally improved the overall survival, illustrating the profound impact of treat-
ment resistance. Thus present therapies, which mostly follow total elimination of rapidly divid-
ing and differentiated tumor cells, need to be modified to target TICs that are able to
repopulate the tumor [14]. Compared to their differentiated counterparts, SC showed
increased resistance to 5-FU, a conventional chemotherapeutic agent, often used in CRC [62].
Noteworthy, all SC derived from traditional cell lines (HCT116 and HT29) and primary cul-
tures do present the same mutational profile as their respective differentiated counterparts,
suggesting that the higher resistance of SC might not be due to differences in mutations. Along
this line, we identified a sphere gene signature that could predict patient outcome in CRC.
Interestingly, 7 genes out of the 8-gene signature are known to be involved in tumorigenesis
and their function is described in S6 Table. We found two genes, CDA and GSTA4, to be linked
with disease relapse in CRC. Recently, CDA was identified as a regulator of cell proliferation
and chemoresistance in breast and pancreatic cancer [52,53]. In CRC genomic variations of
CDA are associated with adverse drug response [63]. Most importantly, high expression of
CDA was found in blood from CRC patients [64], hinting to a potential use of CDA as a
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diagnostic marker. GSTA4 is up-regulated in tumor cells during drug resistance to cisplatin
and doxorubicin [54,65,66]. This part of the gene signature nicely supports our findings
regarding resistance of our established SC to chemotherapeutics. The obtained differential
gene expression in SC relative to their respective differentiated counterparts may partly be a
result of the different cell culture media, one containing growth factors (EGF and FGF) and the
other not. Despite these differences, genes with clinical relevance in regard to disease recur-
rence could be identified in a large independent cohort of CRC patients. This finding requires
confirmation in additional large cohort studies of CRC patients and the exact role of each gene
in TIC function and chemoresistance will be the focus of future investigations. Taken together,
we provide evidence that SC derived from primary tumor tissue represent a powerful tool to
study the mechanisms of chemotherapy resistance and thereby identify new targets for CRC.
Lately several other groups attempted to isolate TICs from traditional CRC cell lines with
conflicting results [20,29,31,32,34,45,60,67–71]. Several studies showed that SC derived from
different types of cancer cell lines are more efficient in initiating tumors than adherent mono-
layers [68,71]. In contrast to these studies, Calvet and colleagues suggest that SC enrich for
TICs in a cell line–dependent manner [35]. In their study, sphere formation could not be con-
sidered as an efficient method to enrich for TICs in murine melanoma and breast cancer cell
lines, although the results were not conclusive for the CRC cell line HT29. Additionally, TICs
derived from primary human gliomas have been reported to undergo spontaneous differentia-
tion and apoptosis in SC thereby limiting the stem cell behavior of these cultures compared to
adherent culture conditions [72]. One might argue that growth factors access an adherent cul-
ture in a more uniform way and thus prevent spontaneous differentiation events enabling
expansion of a TIC-enriched population [72]. By performing medium switch experiments,
Ahmad and colleagues propose that differences in self-renewal are rather due to the type of
medium used and not associated with the fact of the cells being cultured as spheres or adherent
cells, supporting the idea that SC are biologically not more relevant in regard to TIC character-
istics than monolayers [36]. In the context of CRC cell lines, colon spheres derived from the
Caco-2 cell line lost several TIC properties compared to their parental adherent counterpart
[32]. Similar observations were made for the HCT116 cell line by Kai and colleagues, where the
authors suggested that HCT116-derived SC follow a more stochastic model than a TIC model
[60]. Recently, Collura and colleagues performed an extensive characterization of 25 estab-
lished CRC cell lines and concluded that SC do not seem to present TIC features in regard to
tumor-initiating potential but maintain their chemoresistance ability compared to adherent
culturing methods [29]. Using sphere formation assays by seeding single cells per well, our SC
derived from traditional cell lines showed high self-renewal capacity, which is in line with the
expression of stemness proteins. In agreement with the study by Collura and colleagues, we
demonstrate that SC-derived cells show increased chemoresistance compared to adherent dif-
ferentiated cells [29]. In contrast to the study by Ahmad and colleagues, the chemoresistance
ability is maintained while cells derived from SC are switched to differentiating culture condi-
tions [36]. These results clearly demonstrate that SC better preserve chemoresistance features
of primary cells.
Recent evidence indicates that Wnt signaling activity may serve as a functional designation
of TICs [27]. LGR5, a member of the Wnt signaling pathway, has been described as a marker
for stem-like cells in CRC [73]. Interestingly, LGR5 is higher expressed in SC derived from pri-
mary tumor tissue than from traditional cell lines, hinting to a potential enhanced TIC pheno-
type in SC derived from primary patient biopsies compared to cell line-derived SC. However,
the role of LGR5 in CRC is not yet fully understood. While previous studies suggested that
intestinal tumors arise from LGR5-positive cells [74]. Walker and colleagues recently showed
that suppression of LGR5 expression enhances tumorigenesis [75]. In our study, cell line-
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derived SC also show high tumor-initiating capacity similar to primary tumor-derived SC. In
contrast to our findings, a recent study by Fan and colleagues compared fresh clinical specimen
to established cell lines and concluded that only fresh patient tumor material can be used to
isolate TICs [34]. Whereas the authors focus on ALDH activity to isolate TICs we based our
study on functional properties of TICs. In future, we foresee to perform cell sorting based on
the expression of LGR5 and ALDH followed by functional assays.
In conclusion, we demonstrate that SC derived from primary colon tumor tissue display
self-renewal capacity, tumorigenic potential and chemoresistance. SC seem to represent a supe-
rior model to adherent differentiated counterparts to screen for new CRC therapies mostly due
to their increased resistance to chemotherapeutics. Besides, we show that differentiated cells
can rapidly reacquire stem-cell traits which is in line with recent studies demonstrating wide-
spread plasticity and dedifferentiation processes that can affect cancer cells under specific envi-
ronmental conditions [15,27,61]. Finally, our findings underline the clinical pertinence of our
SC, and in future, they may represent an interesting tool to test for new CRC therapies.
Supporting Information
S1 Fig. Fresh patient biopsies are highly heterogeneous in terms of phenotypic markers.
(A) Flow cytometry analysis of surface markers CD24, CD44 and CD133 in fresh resected
tumor tissues from 4 different patients. (B) CD133 does not correlate with enhanced sphere-
forming capacity. SC were sorted according to low, medium and high expression of the surface
marker CD133, followed by a single cell sphere formation assay for CRC cell lines and T6 SC,
data are presented as mean ± SD, ns = not significant. Representative figure from 2 indepen-
dent experiments for HT29 and HCT116 while for T6 one single experiment was performed.
(TIF)
S2 Fig. Mutational profile of the original tumors and established cultures. Several CRC-rel-
evant mutations are shown for primary tumors, primary spheroid (S) and differentiated (D)
cultures for T18 and T20 and for differentiated and spheroid cultures derived from cancer cell
lines HCT116 and HT29. For ethical purposes we were not able to include the mutational pro-
file for patient T6. Top mutations were assessed using the TruSeq Amplicon-Cancer panel
(TSACP), depth> 1000, variant frequency> 0.05. Scale bar represents the number of muta-
tions detected per gene. All mutations found in SC were also present in the differentiated coun-
terpart.
(TIF)
S3 Fig. Differentiated counterparts display a higher proliferative potential compared to
SC. (A) Cell count observed after 5 days of culture for 100 000 cells initially plated. Representa-
tive figure of 2 independent experiments. (B) Spheres of differentiated cultures are bigger than
spheres derived from SC. (C) Colonies derived from differentiated culture T6 are bigger than
colonies from T6 SC. For B-C data are shown T6 for and HT29 and are representative of 2
independent and 1 single experiment for T6 and HT29, respectively. The number of spheres
analysed for size is indicated on the Fig. Data is presented as mean ± SD, P<0.05, P<0.001,
P<0.0001.
(TIF)
S4 Fig. Sphere-forming capacity of established cultures. (A)High numbers of cells form
spheres just by fusion and aggregation, and not due to increased self-renewal properties. Self-
renewal capacity determined by the 1000 cell sphere formation assay of early passage SC grown
from primary tumor tissue and CRC cell lines. Number of spheres observed by plating 1000
cells per well does not correlate to the results of the single cell assay presented in Fig 3, which
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might suggest that fusion and aggregation, rather than self-renewing capacity lead to sphere
formation in the 1000 cell assay. Sphere formation was observed over several generations
(gen.). Data are presented as mean ± SD. (B) Self-renewal capacity determined by the single
cell assay of the differentiated counterparts (late passages) reversed to spheroid culturing con-
ditions or maintained in differentiating culturing conditions, respectively. Sphere formation
was observed over two generations (gen.). Data is shown for T18 and presented as mean ± SD,
P<0.05, P<0.001.
(TIF)
S5 Fig. Sphere-forming capacity of primary and xenograft derived SC. (A) and (B) Self-
renewal capacity, shown by 1000 cell (left panel) and single cell (right panel) sphere forming
assays, is not increased in xenograft-derived SC over several generations (gen.) compared to SC
directly isolated from fresh tumor tissue. Data are presented as mean of 6 replicates ± SD.
Xgen = xenograft-derived generation. (C) Xenograft-derived HCT116 SC grow as loosely
packed aggregates that no longer resemble to spheres. (D)Morphological features of differenti-
ated CRC SC. CRC spheroids adhere and differentiate when grown in medium supplemented
with serum.
(TIF)
S6 Fig. In vivo tumorigenic potential of SC. (A) SC derived from CRC cell lines are able to
induce tumors in mice. (B) Tumor weight of the generated tumor xenografts. n = 5, data are
presented as mean ± SEM. (C) and (D) SC-derived xenografts (S) and xenografts generated
from their differentiated counterparts (D) display similar expression patterns of stemness
genes SOX2, OCT4, NANOG and LGR5. Data are presented as mean ± SD, P<0.05, ns = not
significant, n = 5.
(TIF)
S7 Fig. Gene signature derived from SC predicts poor outcome in CRC patients. (A)Overall
survival curves for CRC patients classified according to gene expression levels for the 8-gene
sphere signature in the datasets GSE29621. (B-C) The expression of two genes from our identi-
fied gene signature (CDA & GSTA4) is linked to an increased risk of disease relapse in the data-
set GSE39582. The number of patients in each group is mentioned within the brackets;
significant p-value is indicated. SC = spheroid cultures, D = differentiated counterparts.
(TIF)
S1 Table. Primary and secondary antibodies used for immunofluorescence analysis and
FACS analysis as well as primer sequences used within the study.
(PDF)
S2 Table. Patient Characteristics.
(PDF)
S3 Table. In vitro limiting dilution assays of CRC spheroid cultures—Sphere forming cell
(SFC) frequency.
(PDF)
S4 Table. In vivo limiting dilution assays of CRC spheroid cultures–number of injected
cells from dissociated spheroids and tumor formation occurrence in mice.
(PDF)
S5 Table. Chemosensitivity assays in SC and differentiated counterparts. A-D. Statistics of
the sphere formation and 5-FU chemosensitivity assay. 2way ANOVA with Bonferroni post-
tests, n = 8, P<0.05, P<0.01, P<0.001, S = Spheres, D = Differentiated counterpart. E-F
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Percentages of colony formation in SC and differentiated counterparts after 5FU treatment.
(PDF)
S6 Table. Genes from the 8-gene signature and their functions.
(PDF)
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